APOE · rs121918397
Where this position leads
Strength of the evidence
There is no record yet to score this position by (a ClinVar disease classification or a genome-wide significant study). That is not the same as weak evidence.
4: ClinVar disease-causing, reviewed by an expert panel or a guideline (3–4 stars). 3: ClinVar, several labs agreeing (2 stars), or a genetic study at p ≤ 10−50. 2: ClinVar from one lab (1 star), or p ≤ 10−20. 1: ClinVar submitted without criteria (0 stars), or genome-wide significance (p ≤ 5×10−8). The higher of the two counts. It says how solid the evidence is, not whether it matters for a particular person.
What ClinVar records
Classification
Conflicting classifications of pathogenicity for Familial type 3 hyperlipoproteinemia, Lipoprotein glomerulopathy, Familial hypercholesterolemia; criteria provided, conflicting classifications (1 of 4 stars, 3 submitters), last evaluated 2024-06-12.
ClinVar record 17865 NM_000041.4(APOE):c.488G>A (p.Arg163His)
Classification
Uncertain significance for Lipoprotein glomerulopathy; criteria provided, single submitter (1 of 4 stars, 1 submitter), last evaluated 2022-05-22.
ClinVar record 1687222 NM_000041.4(APOE):c.488G>T (p.Arg163Leu)
Classification
Pathogenic for Lipoprotein glomerulopathy; no assertion criteria provided (0 of 4 stars, 1 submitter), last evaluated 2000-10-06.
ClinVar record 17879 NM_000041.4(APOE):c.488G>C (p.Arg163Pro)
Change history MyGeneLog™ keeps a copy of every weekly release from 2026-10-19 and compares them. This position's classification has not changed since.
What this is ClinVar's aggregate record for this position (as of its 2026-10-19 release), not a result about you. A classification describes the variant against the condition named, as laboratories submitted it. Whether a person carries this variant, and what that would mean for them, is a question for a clinical test and a genetic counsellor.
Source: ClinVar VCV000017879, no assertion criteria provided
rs121918397 is a single position in the genome, in or near the APOE gene. Published research associates it with lipoprotein glomerulopathy. A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.
APOE carries pharmacogenomic findings for Lecanemab and other anti-amyloid antibodies. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.
No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.
ClinVar VCV000017879, no assertion criteria provided. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Lipoprotein glomerulopathy (rs121918397). MyGeneLog™. https://www.mygenelog.com/variants/rs121918397